Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS -mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial
Gandara, David R., Hiret, Sandrine, Blumenschein, George R., Barlesi, Fabrice, Delord, Jean-Pierre, Madelaine, Jeannick, Infante, Jeffrey R., Reckamp, Karen L., Lara, Primo, Audebert, Christine, Cho, Byoung Chul, Park, Keunchil, Braiteh, Fadi S., Jotte, Robert M., Wu, Yuehui, Schramek, Daniel J., Piepszak, Alexandra M., Gardner, Olivia S., Peddareddigari, Vijay Gopal Reddy, Leighl, Natasha B.
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
Bioequivalence study with lapatinib powder for oral suspension and the original tablet formulation in cancer patients
Koch, Kevin M., Ferron-Brady, Geraldine, Lemmon, Colleen, Cartee, Leanne, Hollyfield, Hedy, D'Amelio Jr, Anthony M., Piepszak, Alexandra, Swaby, Ramona F., Curran, David, Arya, Niki
Published in Clinical pharmacology in drug development (01.05.2015)
Published in Clinical pharmacology in drug development (01.05.2015)
Get full text
Journal Article